Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

78.88 +0.05 (+0.06%)
Streaming Delayed Price Updated: 12:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,622,729
Open 79.06
Bid (Size) 78.87 (2)
Ask (Size) 78.89 (1)
Prev. Close 78.83
Today's Range 78.66 - 79.54
52wk Range 73.31 - 133.43
Shares Outstanding 2,531,374,696
Dividend Yield 4.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants
CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials. 
Via Benzinga
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection. 
Via Stocktwits

Performance

YTD
-20.5%
-20.5%
1 Month
+1.7%
+1.7%
3 Month
-10.0%
-10.0%
6 Month
-21.0%
-21.0%
1 Year
-40.0%
-40.0%

More News

Read More
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
Via Benzinga
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
2 Stocks Too Cheap to Ignore at These Prices
Via The Motley Fool
Topics Artificial Intelligence Lawsuit
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group
Via Benzinga
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
From Merck & Co., Inc.
Via Business Wire
Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy
Via Benzinga
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
Via Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Via Benzinga
2 Reasons to Watch MRK and 1 to Stay Cautious
Via StockStory
Topics Supply Chain
Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals
Via Chartmill
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
3 Mega-Cap Stocks with Competitive Advantages
Via StockStory
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
Via Stocktwits
Topics Government
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
Via The Motley Fool
Topics Government Intellectual Property Lawsuit
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Via Benzinga
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish
Via Stocktwits
Topics Death
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 78.88
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/27/25 12:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 199.67B
How many shares of Merck & Co are outstanding?
Merck & Co has 200B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.